Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
As a newly discovered tuberculosis susceptibility gene, ASAP1 was first discovered by Cambridge University researchers through the GWAS (Genome-Wide Association Study). Afterward, the researchers conducted ASAP1 association studies and linkage analysis in different regions and ethnic groups and made a preliminary investigation of the function of ASAP1 and the mechanism affecting tuberculosis. Tuberculosis (TB) is one of the chronic infectious diseases that are currently a serious threat to human health. It is mainly caused by Mycobacterium tuberculosis (Mtb).
ASAP ribosylation factor-GTPase activating protein is a GTPase activating protein of ADP-ribosylation factors (Arf). The Arf family protein has a molecular weight of about 20 kDa and belongs to the small G protein. It is widely present in eukaryotes and is highly conserved in evolution. It is mainly involved in the regulation of membrane transport and the cytoskeleton. Arf has two binding states in cells, which bind to GTP as an active state and bind to GDP in an inactive state. Guanine nucleotide-exchange factor (GEF) and GTPase-activating protein (GAP) regulate the switch between the two binding states. ASAP1 belongs to the GAP protein that regulates Arf, also known as AMAP1 or Centaurinβ, and is a negative regulator of Arf. ASAP1 recognizes Arf·GTP and induces hydrolysis of GTP to form Arf·GDP, which inactivates Arf function.
Figure 1. Model for ASAP1 interaction with NM2A regulated by PIP2 and Arf. (Luo, R., et al. 2017)
In the model studied by Luo, PIP2, which binds to the PH-domain of AsAP1, promotes the binding of ARFGTP to ASAP1. ASAP1 undergoes a conformational change in interaction with NM2A, and subsequent AGFTTP hydrolysis induces ASAP1 to further promote a conformational change in NM2A activity and return ASAP1 to a conformation capable of another round of NM2A binding.
ASAP1 Function and Its Mechanism of Affecting Human Tuberculosis Susceptibility
ASAP1 functions mainly focus on intracellular endocytosis, intracellular vesicle transport, and cytoskeletal regulation, as well as tumor metastasis and spread. Tien et al. found that ASAP1 negatively regulates the signaling pathway of NF-kB, a transcription factor that regulates inflammatory responses in cells, suggesting that ASAP1 may become a new target for the treatment of inflammatory response. Ruggiero et al. found that a complex called KDELR, which is located in the Golgi apparatus, functions to degrade the extracellular matrix by increasing the cell structure of the foot process. The function of the foot process is dependent on the phosphorylation of ASAP1 by KDELR. The indirect reaction of ASAP1 is necessary for the degradation of the extracellular matrix. Davidson et al. found a mechanism of cell actin reorganization that relies on Arf6, a mechanism that enhances Salmonella infection. It is also pointed out that the equilibrium relationship between Arf GEFs and Arf GAPs is beneficial to the phagocytosis of Salmonella by host cells.
At present, the research on the mechanism of ASAP1 protein affecting the susceptibility of human tuberculosis is still in the exploration stage. Nowadays, it mainly focuses on the regulation of ASAP1 protein expression on the migration ability of immune cells, which in turn affects human susceptibility to TB. Curtis et al. detected the mRNA content of ASAP1 in Mtb-infected dendritic cells (DC) by qRT-PCR and found that its expression was significantly reduced. At the same time, the ability of infected DCs to migrate and phagocytic lysosome formation is reduced.
Tripathi et al. combined with flow cytometry and confocal microscopy revealed a significant reduction in the expression of β2 (CD18) integrin on the surface of Mtb-infected dendritic cells. At the same time, the αL (CD11a) and αM (CD11b) integrin subunits were also relatively reduced and showed a decrease in the adhesion of DC to the lung endothelial cell layer and a decrease in the migration ability of lymphokines. Eventually, the presentation of antigen by innate immune cells is weakened, and the occurrence of adaptive immunity is delayed, so that Mtb is more widely spread and distributed in vivo. Based on the above-mentioned susceptibility mechanism of TB and the function of ASAP1 protein, it is speculated that ASAP1 protein mainly affects the migration ability of immune cells, which in turn affects the immune process of pathogens.
ASAP1 Gene and Susceptibility to Tuberculosis
Curtis's genome-wide association analysis (GWAS) of 5,914 active TB patients and 6022 healthy volunteers from St. Petersburg, Russia, a high-incidence area in the world, found that 11 SNPs (Single Nucleotide Polymorphisms) of ASAP1 were significantly associated with TB susceptibility, and they all distributed in introns. The further statistical analysis was performed on 7 significant related SNPs, and the four most relevant SNP loci (rs10956514, rs1469288, rs2033059, rs4733781) were obtained. It is preliminarily concluded that the mechanism of ASAP1 affecting host susceptibility weakens the migration of DC and the degradation of extracellular matrix, slows down the innate immune process, and enhances the viability and invasiveness of intracellular parasites.
Hu applied the iMLDR method to 1115 western Han population and 914 Tibetan population to classify 7 SNP loci of ASAP1, and then combined with meta-analysis to further explore the correlation between ASAP1 and TB. Data comparison showed that there was no significant correlation between ASAP1 and TB susceptibility in the Chinese population. Miao et al. used TaqMan allelic discrimination in 355 Chinese patients with recent tuberculosis infection and 395 healthy people to analyze the two SNPs of ASAP1. It was found that ASAP1 and TB susceptibility were not significantly correlated in the Chinese population. This again illustrates the relationship between genetic polymorphism and disease that emphasizes ethnic differences.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.